{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T20:41:43Z","timestamp":1759178503431},"reference-count":54,"publisher":"Elsevier BV","issue":"36","license":[{"start":{"date-parts":[[2010,8,1]],"date-time":"2010-08-01T00:00:00Z","timestamp":1280620800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2010,8]]},"DOI":"10.1016\/j.vaccine.2010.06.068","type":"journal-article","created":{"date-parts":[[2010,7,17]],"date-time":"2010-07-17T08:38:38Z","timestamp":1279355918000},"page":"5828-5836","source":"Crossref","is-referenced-by-count":12,"title":["Conjugation of HPV16 E7 to cholera toxin enhances the HPV-specific T-cell recall responses to pulsed dendritic cells in vitro in women with cervical dysplasia"],"prefix":"10.1016","volume":"28","author":[{"given":"Merja","family":"Nurkkala","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lotta","family":"Wass\u00e9n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inger","family":"Nordstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inger","family":"Gustavsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucija","family":"Slavica","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agnetha","family":"Josefsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristina","family":"Eriksson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl. 2","key":"10.1016\/j.vaccine.2010.06.068_bib1","doi-asserted-by":"crossref","first-page":"SII23","DOI":"10.1016\/S0140-6736(97)90017-9","article-title":"Global burden of cancer","volume":"349","author":"Boyle","year":"1997","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.vaccine.2010.06.068_bib2","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3322\/canjclin.48.1.6","article-title":"Cancer statistics, 1998","volume":"48","author":"Landis","year":"1998","journal-title":"CA Cancer J Clin"},{"issue":"11","key":"10.1016\/j.vaccine.2010.06.068_bib3","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1093\/jnci\/87.11.796","article-title":"Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group","volume":"87","author":"Bosch","year":"1995","journal-title":"J Natl Cancer Inst"},{"issue":"5A","key":"10.1016\/j.vaccine.2010.06.068_bib4","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0002-9343(97)00177-0","article-title":"Epidemiology of genital human papillomavirus infection","volume":"102","author":"Koutsky","year":"1997","journal-title":"Am J Med"},{"issue":"5","key":"10.1016\/j.vaccine.2010.06.068_bib5","first-page":"483","article-title":"Regression of cervical intraepithelial neoplasia and loss of human papillomavirus (HPV) infection is associated with cell-mediated immune responses to an HPV type 16 E7 peptide","volume":"11","author":"Kadish","year":"2002","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"6","key":"10.1016\/j.vaccine.2010.06.068_bib6","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1093\/ajcp\/102.6.768","article-title":"Immunological events in regressing genital warts","volume":"102","author":"Coleman","year":"1994","journal-title":"Am J Clin Pathol"},{"issue":"6","key":"10.1016\/j.vaccine.2010.06.068_bib7","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1002\/ijc.2910570612","article-title":"Cellular immunodeficiency enhances the progression of human papillomavirus-associated cervical lesions","volume":"57","author":"Petry","year":"1994","journal-title":"Int J Cancer"},{"issue":"9246","key":"10.1016\/j.vaccine.2010.06.068_bib8","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1016\/S0140-6736(00)03315-8","article-title":"Spontaneous regression of CIN and delayed-type hypersensitivity to HPV-16 oncoprotein E7","volume":"356","author":"Hopfl","year":"2000","journal-title":"Lancet"},{"issue":"7\u20138","key":"10.1016\/j.vaccine.2010.06.068_bib9","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1345\/aph.1G723","article-title":"Human papillomavirus vaccines","volume":"40","author":"Schmiedeskamp","year":"2006","journal-title":"Ann Pharmacother"},{"issue":"2","key":"10.1016\/j.vaccine.2010.06.068_bib10","doi-asserted-by":"crossref","first-page":"92","DOI":"10.4103\/0973-1482.34686","article-title":"Quadrivalent human papillomavirus recombinant vaccine: the first vaccine for cervical cancers","volume":"3","author":"Sharma","year":"2007","journal-title":"J Cancer Res Ther"},{"issue":"7","key":"10.1016\/j.vaccine.2010.06.068_bib11","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S1473-3099(07)70158-5","article-title":"Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis","volume":"7","author":"de Sanjose","year":"2007","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2010.06.068_bib12","doi-asserted-by":"crossref","first-page":"106","DOI":"10.3322\/canjclin.56.2.106","article-title":"Cancer statistics, 2006","volume":"56","author":"Jemal","year":"2006","journal-title":"CA Cancer J Clin"},{"issue":"2\u20133","key":"10.1016\/j.vaccine.2010.06.068_bib13","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1159\/000050044","article-title":"Therapeutic vaccines for human papillomaviruses","volume":"44","author":"Gissmann","year":"2001","journal-title":"Intervirology"},{"issue":"2 Suppl","key":"10.1016\/j.vaccine.2010.06.068_bib14","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1016\/j.ygyno.2008.02.003","article-title":"Immunobiology of HPV and HPV vaccines","volume":"109","author":"Stanley","year":"2008","journal-title":"Gynecol Oncol"},{"issue":"8","key":"10.1016\/j.vaccine.2010.06.068_bib15","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.humpath.2004.04.007","article-title":"Vaccination to prevent and treat cervical cancer","volume":"35","author":"Roden","year":"2004","journal-title":"Hum Pathol"},{"issue":"6673","key":"10.1016\/j.vaccine.2010.06.068_bib16","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/32588","article-title":"Dendritic cells and the control of immunity","volume":"392","author":"Banchereau","year":"1998","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.vaccine.2010.06.068_bib17","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1038\/nm1295-1297","article-title":"Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity","volume":"1","author":"Mayordomo","year":"1995","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.vaccine.2010.06.068_bib18","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/S0952-7915(03)00015-3","article-title":"The use of dendritic cells in cancer immunotherapy","volume":"15","author":"Schuler","year":"2003","journal-title":"Curr Opin Immunol"},{"issue":"5","key":"10.1016\/j.vaccine.2010.06.068_bib19","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1172\/JCI31205","article-title":"DC-based cancer vaccines","volume":"117","author":"Gilboa","year":"2007","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.vaccine.2010.06.068_bib20","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F","article-title":"Human papillomavirus is a necessary cause of invasive cervical cancer worldwide","volume":"189","author":"Walboomers","year":"1999","journal-title":"J Pathol"},{"issue":"3","key":"10.1016\/j.vaccine.2010.06.068_bib21","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.ygyno.2005.09.040","article-title":"HPV16\/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities","volume":"100","author":"Santin","year":"2006","journal-title":"Gynecol Oncol"},{"issue":"9","key":"10.1016\/j.vaccine.2010.06.068_bib22","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s00432-003-0463-5","article-title":"Dendritic cell-based tumor vaccine for cervical cancer II: results of a clinical pilot study in 15 individual patients","volume":"129","author":"Ferrara","year":"2003","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"10.1016\/j.vaccine.2010.06.068_bib23","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.clim.2004.03.001","article-title":"Vaccination with dendritic cells pulsed in vitro with tumor antigen conjugated to cholera toxin efficiently induces specific tumoricidal CD8+ cytotoxic lymphocytes dependent on cyclic AMP activation of dendritic cells","volume":"112","author":"Sun","year":"2004","journal-title":"Clin Immunol"},{"issue":"4","key":"10.1016\/j.vaccine.2010.06.068_bib24","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1128\/IAI.71.4.1740-1747.2003","article-title":"Cholera toxin and its B subunit promote dendritic cell vaccination with different influences on Th1 and Th2 development","volume":"71","author":"Eriksson","year":"2003","journal-title":"Infect Immun"},{"issue":"8","key":"10.1016\/j.vaccine.2010.06.068_bib25","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1002\/1521-4141(2000)30:8<2394::AID-IMMU2394>3.0.CO;2-Y","article-title":"Cholera toxin induces maturation of human dendritic cells and licences them for Th2 priming","volume":"30","author":"Gagliardi","year":"2000","journal-title":"Eur J Immunol"},{"issue":"32","key":"10.1016\/j.vaccine.2010.06.068_bib26","doi-asserted-by":"crossref","first-page":"6037","DOI":"10.1016\/j.vaccine.2007.05.041","article-title":"Therapeutic dendritic cell vaccination with Ag coupled to cholera toxin in combination with intratumoural CpG injection leads to complete tumour eradication in mice bearing HPV 16 expressing tumours","volume":"25","author":"Chandy","year":"2007","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2010.06.068_bib27","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.jcv.2009.04.012","article-title":"Comparison between the Hybrid Capture 2 and the hpVIR real-time PCR for detection of human papillomavirus in women with ASCUS or low grade dysplasia","volume":"45","author":"Gustavsson","year":"2009","journal-title":"J Clin Virol"},{"issue":"1","key":"10.1016\/j.vaccine.2010.06.068_bib28","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0166-0934(01)00361-5","article-title":"Determination of the binding affinity of different human papillomavirus E7 proteins for the tumour suppressor pRb by a plate-binding assay","volume":"98","author":"Dong","year":"2001","journal-title":"J Virol Methods"},{"issue":"7","key":"10.1016\/j.vaccine.2010.06.068_bib29","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1046\/j.1365-2222.2000.00849.x","article-title":"Prolonged oral treatment with low doses of allergen conjugated to cholera toxin B subunit suppresses immunoglobulin E antibody responses in sensitized mice","volume":"30","author":"Rask","year":"2000","journal-title":"Clin Exp Allergy"},{"issue":"6","key":"10.1016\/j.vaccine.2010.06.068_bib30","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1128\/JCM.10.6.791-795.1979","article-title":"Evaluation of a ganglioside immunosorbent assay for detection of Escherichia coli heat-labile enterotoxin","volume":"10","author":"Back","year":"1979","journal-title":"J Clin Microbiol"},{"issue":"36","key":"10.1016\/j.vaccine.2010.06.068_bib31","doi-asserted-by":"crossref","first-page":"33369","DOI":"10.1074\/jbc.M112337200","article-title":"Detoxification of cholera toxin without removal of its immunoadjuvanticity by the addition of (STa-related) peptides to the catalytic subunit. A potential new strategy to generate immunostimulants for vaccination","volume":"277","author":"Sanchez","year":"2002","journal-title":"J Biol Chem"},{"issue":"2","key":"10.1016\/j.vaccine.2010.06.068_bib32","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/sj.bjc.6602679","article-title":"T-cell responses to human papillomavirus type 16 among women with different grades of cervical neoplasia","volume":"93","author":"Steele","year":"2005","journal-title":"Br J Cancer"},{"issue":"17","key":"10.1016\/j.vaccine.2010.06.068_bib33","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1093\/jnci\/89.17.1285","article-title":"Lymphoproliferative responses to human papillomavirus (HPV) type 16 proteins E6 and E7: outcome of HPV infection and associated neoplasia","volume":"89","author":"Kadish","year":"1997","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"10.1016\/j.vaccine.2010.06.068_bib34","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1084\/jem.189.3.541","article-title":"Cholera toxin suppresses interleukin (IL)-12 production and IL-12 receptor beta1 and beta2 chain expression","volume":"189","author":"Braun","year":"1999","journal-title":"J Exp Med"},{"issue":"6","key":"10.1016\/j.vaccine.2010.06.068_bib35","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1084\/jem.20080912","article-title":"Cholera toxin inhibits IL-12 production and CD8alpha+ dendritic cell differentiation by cAMP-mediated inhibition of IRF8 function","volume":"206","author":"la Sala","year":"2009","journal-title":"J Exp Med"},{"issue":"2","key":"10.1016\/j.vaccine.2010.06.068_bib36","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/nri1001","article-title":"Interleukin-12 and the regulation of innate resistance and adaptive immunity","volume":"3","author":"Trinchieri","year":"2003","journal-title":"Nat Rev Immunol"},{"issue":"7\u20138","key":"10.1016\/j.vaccine.2010.06.068_bib37","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/0923-2494(96)83011-2","article-title":"Interleukin-12: a proinflammatory cytokine with immunoregulatory functions","volume":"146","author":"Trinchieri","year":"1995","journal-title":"Res Immunol"},{"issue":"3","key":"10.1016\/j.vaccine.2010.06.068_bib38","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1002\/cncr.22428","article-title":"Role of tumor-derived proinflammatory cytokines GM-CSF, TNF-alpha, and IL-12 in the migration and differentiation of antigen-presenting cells in cervical carcinoma","volume":"109","author":"Zijlmans","year":"2007","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.vaccine.2010.06.068_bib39","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.ygyno.2003.12.022","article-title":"A phase II trial of interleukin-12 in patients with advanced cervical cancer: clinical and immunologic correlates. Eastern Cooperative Oncology Group study E1E96","volume":"92","author":"Wadler","year":"2004","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.vaccine.2010.06.068_bib40","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/j.1600-065X.2008.00616.x","article-title":"Multiple roles for CD4+ T cells in anti-tumor immune responses","volume":"222","author":"Kennedy","year":"2008","journal-title":"Immunol Rev"},{"issue":"37\u201339","key":"10.1016\/j.vaccine.2010.06.068_bib41","doi-asserted-by":"crossref","first-page":"6199","DOI":"10.1016\/j.vaccine.2006.05.108","article-title":"Maintenance of CD8 effector T cells by CD4 helper T cells eradicates growing tumors and promotes long-term tumor immunity","volume":"24","author":"Lin","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2010.06.068_bib42","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1146\/annurev.immunol.23.021704.115825","article-title":"Cooperation between CD4+ and CD8+ T cells: when, where, and how","volume":"24","author":"Castellino","year":"2006","journal-title":"Annu Rev Immunol"},{"issue":"15","key":"10.1016\/j.vaccine.2010.06.068_bib43","doi-asserted-by":"crossref","first-page":"5449","DOI":"10.1158\/0008-5472.CAN-04-0831","article-title":"Human papillomavirus type 16-positive cervical cancer is associated with impaired CD4+ T-cell immunity against early antigens E2 and E6","volume":"64","author":"de Jong","year":"2004","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.vaccine.2010.06.068_bib44","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1111\/j.1525-1438.2007.00883.x","article-title":"Cytokine profile in Indian women with cervical intraepithelial neoplasia and cancer cervix","volume":"17","author":"Sharma","year":"2007","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"10.1016\/j.vaccine.2010.06.068_bib45","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1128\/CDLI.8.2.209-220.2001","article-title":"Cell-mediated immune response to human papillomavirus infection","volume":"8","author":"Scott","year":"2001","journal-title":"Clin Diagn Lab Immunol"},{"issue":"3","key":"10.1016\/j.vaccine.2010.06.068_bib46","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.ygyno.2007.11.006","article-title":"Interferon-gamma (IFN-gamma): a possible prognostic marker for clearance of high-risk human papillomavirus (HPV)","volume":"108","author":"Song","year":"2008","journal-title":"Gynecol Oncol"},{"issue":"9","key":"10.1016\/j.vaccine.2010.06.068_bib47","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s00432-003-0462-6","article-title":"Dendritic cell-based tumor vaccine for cervical cancer I: in vitro stimulation with recombinant protein-pulsed dendritic cells induces specific T cells to HPV16 E7 or HPV18 E7","volume":"129","author":"Nonn","year":"2003","journal-title":"J Cancer Res Clin Oncol"},{"issue":"6","key":"10.1016\/j.vaccine.2010.06.068_bib48","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1086\/315498","article-title":"Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection","volume":"181","author":"Carter","year":"2000","journal-title":"J Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2010.06.068_bib49","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1067\/mob.2003.98","article-title":"Evaluation of antibody response to human papillomavirus early proteins in women in whom cervical cancer developed 1 to 20 years later","volume":"188","author":"Lehtinen","year":"2003","journal-title":"Am J Obstet Gynecol"},{"issue":"1","key":"10.1016\/j.vaccine.2010.06.068_bib50","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1158\/1055-9965.EPI-03-0191","article-title":"Natural history of human papillomavirus type 16 virus-like particle antibodies in young women","volume":"13","author":"Ho","year":"2004","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"3","key":"10.1016\/j.vaccine.2010.06.068_bib51","first-page":"636","article-title":"Frequent display of human papillomavirus type 16 E6-specific memory t-Helper cells in the healthy population as witness of previous viral encounter","volume":"63","author":"Welters","year":"2003","journal-title":"Cancer Res"},{"issue":"9","key":"10.1016\/j.vaccine.2010.06.068_bib52","doi-asserted-by":"crossref","first-page":"5716","DOI":"10.1128\/IAI.69.9.5716-5725.2001","article-title":"Cholera toxin B subunit as a carrier molecule promotes antigen presentation and increases CD40 and CD86 expression on antigen-presenting cells","volume":"69","author":"George-Chandy","year":"2001","journal-title":"Infect Immun"},{"issue":"5","key":"10.1016\/j.vaccine.2010.06.068_bib53","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1002\/eji.200324368","article-title":"Coupling of antigen to cholera toxin for dendritic cell vaccination promotes the induction of MHC class I-restricted cytotoxic T cells and the rejection of a cognate antigen-expressing model tumor","volume":"34","author":"Eriksson","year":"2004","journal-title":"Eur J Immunol"},{"issue":"4","key":"10.1016\/j.vaccine.2010.06.068_bib54","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1128\/JVI.02343-07","article-title":"Human papillomavirus type 16 and 18 E7-pulsed dendritic cell vaccination of stage IB or IIA cervical cancer patients: a phase I escalating-dose trial","volume":"82","author":"Santin","year":"2008","journal-title":"J Virol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X10008960?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X10008960?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,6,7]],"date-time":"2020-06-07T04:22:06Z","timestamp":1591503726000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X10008960"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8]]},"references-count":54,"journal-issue":{"issue":"36","published-print":{"date-parts":[[2010,8]]}},"alternative-id":["S0264410X10008960"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2010.06.068","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2010,8]]}}}